BMJ Meta-Analysis: Calcium and Vitamin D Do Little for Fractures in Average-Risk Older Adults

*Originally surfaced May 21, 2026.*

A systematic review and meta-analysis published in The BMJ in May 2026 pooled data from 69 randomized controlled trials covering nearly 154,000 adults and concluded that calcium, vitamin D, or combined supplementation provides little to no clinically meaningful benefit for fracture or fall prevention in older adults who are not at increased risk. The authors framed the finding as a reason not to recommend these supplements routinely in the general adult population.

This lands in the middle of a longer story. The bone-health argument for blanket vitamin D and calcium supplementation has been weakening for several years, with prior USPSTF analyses raising similar concerns. The BMJ paper is the most recent and one of the largest pooled analyses.

## What the paper actually says, and what it does not

The paper is about average-risk older adults. It is not about people with documented vitamin D deficiency, established osteoporosis, malabsorption conditions, prior fragility fracture, or specific high-risk profiles. It does not argue that vitamin D is useless in those populations. It does argue that giving everyone in the general older-adult population a calcium or vitamin D supplement on autopilot is poorly supported by the trial evidence.

Experts cited in the coverage cautioned that the findings should not change existing osteoporosis guidelines, which target high-risk patients for whom the evidence base is different.

## What this means for testing-first thinking

If the blanket supplementation case is weak, the case for measuring first becomes stronger. There is a real difference between supplementing because every wellness influencer says to and supplementing because a measured serum 25-hydroxyvitamin D level indicates deficiency or insufficiency.

The vitamin D test measures 25-hydroxyvitamin D, which is the standard marker of vitamin D status. A clinician can then decide whether supplementation is warranted, at what dose, and for how long, with a follow-up measurement to confirm response. That sequence is what the evidence supports, and it is also what the BMJ paper implicitly endorses: target the people who actually have a deficit, not the whole population.

For a broader baseline alongside vitamin D status, the comprehensive health profile covers general chemistry, kidney and liver function, and other markers that matter when thinking about bone and mineral context.

For background, see our vitamin D deficiency page.

This article is editorial commentary and is not medical advice. Supplementation decisions, especially around osteoporosis and fall prevention, should be made with a clinician familiar with your personal risk profile.